Health CanadaGeneral Alert
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/...
Published: February 3, 2022Recall ID: 63879Category: generalCountry: Canada
Reason for Recall / Hazard
New safety information - Product safety
Product Description & Identification
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
Affected Products
BEOVU (brolucizumab)
Additional Source Details
| Field | Value |
|---|---|
| N I D | 63879 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/beovu-brolucizumab-risk-intraocular-inflammation-retinal-vasculitis-andor-retinal |
| Issue | New safety information - Product safety |
| Title | BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion |
| Product | BEOVU (brolucizumab) |
| Archived | 0 |
| Category | Drugs |
| Last updated | 2022-02-03 |
| Organization | Marketed health products |